LAW
Amgen Refocuses Pipeline, Prioritizes Obesity Therapies Amid Strategic Cuts
Amgen, Obesity Therapies, Pipeline Cuts, Strategic Refocus, MariTide, Phase 3 Program
Blue Earth Therapeutics Advances with $76.5M Series A Financing for Next-Gen Radiohybrid RLTs
Blue Earth Therapeutics, Series A financing, radiohybrid RLTs, Phase II studies, targeted therapies, lutetium, alpha emitter.
Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis
Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance
Federal Court Dismisses Novartis’ Challenge to Inflation Reduction Act, Marking Sixth Win for Government
Inflation Reduction Act, IRA lawsuit, Novartis, Medicare Drug Price Negotiation Program, federal court, pharmaceutical industry, government victory
Gilead and Merck’s Investigational HIV Combo Shows Promising Long-Term Viral Suppression in Phase 2 Trial
HIV treatment, Weekly oral regimen, Islatravir, Lenacapavir, Viral suppression, Phase 2 clinical trial, Gilead Sciences, Merck & Co.
MeiraGTx Announces Positive Phase 2 Data for AAV-GAD Gene Therapy in Parkinson’s Disease, Paving Way for Phase 3 Trial
MeiraGTx, AAV-GAD, Gene Therapy, Parkinson’s Disease, Phase 2 Trial, Phase 3 Trial, Neurodegenerative Disorders, Genetic Medicine
Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment
Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical
Gritstone Bio Files for Chapter 11 Bankruptcy, Casting Uncertainty Over Cancer Vaccine Development
Gritstone Bio, Chapter 11 bankruptcy, cancer vaccine, financial restructuring, clinical trials, immunotherapy, vaccine development.
Gritstone Bio Files for Chapter 11 Bankruptcy, Seeks Strategic Alternatives to Preserve Clinical Research
Gritstone Bio, Chapter 11 bankruptcy, strategic alternatives, clinical research, vaccine development, oncology, infectious diseases
Travere Therapeutics Pauses Phase 3 HARMONY Study Due to Manufacturing Scale-Up Challenges
Travere Therapeutics, Phase 3 HARMONY Study, Pegtibatinase, Classical Homocystinuria, Manufacturing Scale-Up Issue